MapLight Therapeutics Files S-8 for Employee Stock Plans
Ticker: MPLT · Form: S-8 · Filed: Mar 26, 2026 · CIK: 0001770069
Complexity: simple
Sentiment: neutral
Topics: employee-benefits, stock-compensation, dilution, regulatory-filing
TL;DR
**MapLight Therapeutics just cleared the way to give employees more stock, watch for potential dilution.**
AI Summary
MapLight Therapeutics, Inc. filed an S-8 on March 26, 2026, to register securities for its employee benefit plans. This filing allows the company to issue shares to employees, which is a common way to attract and retain talent. For investors, this means potential dilution as more shares could be issued, but it also signals the company's commitment to its workforce, which can be a positive long-term indicator for growth and stability.
Why It Matters
This filing enables MapLight Therapeutics to compensate employees with stock, which can dilute existing shareholder value but is crucial for attracting and retaining top talent in the competitive pharmaceutical industry.
Risk Assessment
Risk Level: low — An S-8 filing is a routine administrative step for companies to register shares for employee benefit plans and does not inherently pose significant immediate risk.
Analyst Insight
Smart investors should monitor future S-8 filings for the number of shares registered, as significant increases could signal substantial dilution, but this specific filing is a standard procedural step.
Key Numbers
- 2026-03-26 — Filing Date (Date the S-8 was filed and accepted by the SEC)
- 0001770069 — CIK (Central Index Key for MapLight Therapeutics, Inc.)
- 333-294620 — File No. (SEC file number for this specific S-8 registration)
- 2834 — SIC Code (Standard Industrial Classification for Pharmaceutical Preparations)
Key Players & Entities
- MapLight Therapeutics, Inc. (company) — Filer of the S-8
- 0001770069 (company) — CIK of MapLight Therapeutics, Inc.
- 832163243 (company) — EIN of MapLight Therapeutics, Inc.
- 333-294620 (dollar_amount) — File number for the S-8
- 2026-03-26 (dollar_amount) — Filing and Acceptance Date
Forward-Looking Statements
- MapLight Therapeutics will continue to use stock-based compensation to attract and retain talent. (MapLight Therapeutics, Inc.) — high confidence, target: 2027-03-26
FAQ
What is the primary purpose of MapLight Therapeutics, Inc.'s S-8 filing?
The primary purpose of MapLight Therapeutics, Inc.'s S-8 filing is to register securities that will be offered to employees through employee benefit plans, as indicated by the form type 'S-8 - Securities to be offered to employees in employee benefit plans'.
When was this S-8 filing submitted and accepted by the SEC?
This S-8 filing was submitted and accepted by the SEC on March 26, 2026, with the 'Filing Date' and 'Accepted' dates both listed as '2026-03-26'.
What is MapLight Therapeutics, Inc.'s CIK number?
MapLight Therapeutics, Inc.'s CIK number is 0001770069, as stated in the 'Filer' section of the filing details.
What is the SIC code for MapLight Therapeutics, Inc. and what does it represent?
MapLight Therapeutics, Inc.'s SIC code is 2834, which represents 'Pharmaceutical Preparations', indicating their primary industry classification.
Where is MapLight Therapeutics, Inc.'s business address located?
MapLight Therapeutics, Inc.'s business address is 800 CHESAPEAKE DRIVE REDWOOD CITY CA 94063, as listed in the 'Business Address' section of the filing.
Filing Stats: 1,483 words · 6 min read · ~5 pages · Grade level 11.5 · Accepted 2026-03-26 07:54:48
Key Financial Figures
- $0.0001 — 1,444 shares of common stock, par value $0.0001 per share ("common stock"), of MapLight
Filing Documents
- d118127ds8.htm (S-8) — 38KB
- d118127dex51.htm (EX-5.1) — 8KB
- d118127dex231.htm (EX-23.1) — 2KB
- d118127dexfilingfees.htm (EX-FILING FEES) — 18KB
- g118127g0325015747981.jpg (GRAPHIC) — 3KB
- 0001193125-26-125105.txt ( ) — 186KB
- d118127dexfilingfees_htm.xml (XML) — 9KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Redwood City, California, on March 26, 2026. MAPLIGHT THERAPEUTICS, INC. By: /s/ Christopher A. Kroeger Christopher A. Kroger, M.D. Chief Executive Officer and Director POWER OF ATTORNEY KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Christopher A. Kroeger, M.D., and Vishwas Setia, and each one of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to sign any registration statement for the same offering covered by this registration statement that is to be effective on filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof. Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacit